The role of endosomal cholesterol trafficking protein, StAR-related lipid transfer domain 3 (StarD3/MLN64), in BRIN-BD11 insulinoma cells by Pinto, Joana Borges & Graham, Annette
LETTER
The role of endosomal cholesterol trafﬁcking
protein, StAR-related lipid transfer domain 3
(StarD3/MLN64), in BRIN-BD11 insulinoma
cells
Dear Editor,
Insulin secretion by pancreatic β-cells is modulated by
altering the cellular content and distribution of cholesterol,
which is tightly regulated by a network of transcription fac-
tors, enzymes, receptors, transporters and cholesterol traf-
ﬁcking proteins. Inhibition of cellular biosynthesis by ‘statin’
drugs, or depletion of plasma membrane cholesterol by
methyl-β-cyclodextrin (MCD), reduce glucose-stimulated
insulin secretion (GSIS) and content in β-cells and islets;
statin treatment also causes delayed ATP production,
inﬂammation and β-cell apoptosis (Tscuhiya et al., 2010;
Zuniga-Hertz et al., 2015). Paradoxically, accumulation of β-
cell/islet cholesterol caused by low density lipoprotein (LDL)
receptor deﬁciency (Souza et al., 2013) or loss of ATP
binding cassette transporters (ABCA1, ABCG1) which efﬂux
cholesterol to apolipoprotein A-I (apo A-I) and high density
lipoprotein (HDL) (Kruit et al., 2012), is also associated with
loss of GSIS, impaired calcium handling, increased reactive
oxygen species (ROS), inﬂammation and apoptosis.
Cholesterol levels within β-cells must therefore remain
within deﬁned limits to maintain insulin release. Sustaining or
improving the efﬁciency of non-vesicular intracellular
cholesterol transport, by targeting key members of the
steroidogenic acute regulatory protein (StAR)-related lipid
transfer (START) domain family, may help achieve this goal.
The START domain of 54kDa endosomal StarD3 (MLN64) is
an helix grip fold, providing a hydrophobic binding site for
one molecule of cholesterol, facilitating cholesterol trafﬁcking
to the endoplasmic reticulum (ER), mitochondria and plasma
membrane (Charman et al., 2010; Alpy et al., 2013; van der
Kant et al., 2013). Our previous work demonstrated regula-
tion of StarD3 expression by lipid-responsive transcription
factors and macrophage sterol content (Borthwick et al.
2009) and repression by genetic obesity in hepatic tissues
(Sofﬁentini et al., 2014), while overexpression of STARD3 in
macrophages enhanced expression of ABCA1 and choles-
terol efﬂux to apoA-I (Borthwick et al., 2010).
Together, these data led to the hypothesis that StarD3
might be an important component of the cholesterol home-
ostasis mechanisms sustaining effective insulin release in β-
cells. This study examines expression of StarD3 after
cholesterol enrichment and depletion, and investigates the
functional impact of StarD3 ligation and of genetically
manipulating expression levels of this protein, on cholesterol
metabolism and insulin release in rodent BRIN-BD11insuli-
noma cells.
A commercial Cholesterol Lipid Concentrate (CLC), con-
taining cholesterol bound to cyclodextrin, was used to
increase the cholesterol content of BRIN-BD11 insulinoma
cells. The effects of treatment (1 h) with dilutions (1:250,
1:200 and 1:100) of CLC, followed by incubation for 24h in
serum-free media, on cell viability, cholesterol biosynthesis
and mass, insulin secretion and expression of StarD3 are
shown in Table 1. Treatment with CLC did not reduce cellular
viability; instead dilutions of 1:200 and 1:100 were associ-
ated with modest (14%; P < 0.01) increases in conversion of
MTT to formazan. Cellular cholesterol mass increased by
50% (P < 0.001) at CLC (1:200), but no changes in
cholesterol biosynthesis were noted at any dilution of CLC
tested. Release of insulin into Krebs buffer containing 5.6
mmol/L glucose (20 min) increased (1.48-fold; P < 0.05)
following treatment with CLC (1:100), but no signiﬁcant
changes in expression of StarD3 protein were noted at any
dilution tested (Table 1).
Cholesterol depletion from BRIN-BD11 cells was
achieved by treatment (1 h) with methyl-β-cyclodextrin
(MCD; 0–10mmol/L), followed by a 24 h recovery period in
serum-free media. No signiﬁcant changes in cellular viability,
as judged by production of formazan were observed
(Table 1). Cholesterol mass decreased by 51% (P < 0.01) in
cells treated with 10mmol/L MCD, reﬂected in the marked
compensatory increase (20.8-fold; P < 0.01) in cholesterol
(20.8-fold; P < 0.01) biosynthesis from [14C]acetate. In cells
radiolabelled with [3H]cholesterol, 1mmol/L MCD and 10
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mmol/L MCD signiﬁcantly increased % cellular radiolabel
extracted by 43.1-fold (P < 0.001) and by 134.7-fold (P <
0.001) respectively, compared with control. Insulin release
(20min) into Krebs buffer (5.6 mmol/L glucose) declined by
33% (P < 0.05) and 45% (P < 0.01) after treatment with
0.1mmol/L and 10mmol/L MCD, respectively (Table 1).
Levels of StarD3 protein ﬂuctuated in cells treated with MCD,
but the changes did not prove signiﬁcant (Table 1), and linear
regression analysis indicated no signiﬁcant correlations with
insulin release, efﬂux biosynthesis, or cholesterol mass.
Together, these data-sets indicate that expression of StarD3
protein remain unaffected by profound changes in ﬂux
between cellular cholesterol pools induced by CLC and MCD
in BRIN-BD11 insulinoma cells.
Treatment of the BRIN-BD11 cells with lutein (0–30 μmol/
L), a carotenoid ligand of StarD3, did not signiﬁcantly alter
viability (Table 1) or induce any signiﬁcant changes in StarD3
protein levels (Fig. 1A), compared with control, indicating
ligation does not change StarD3 protein stability. However,
levels of StarD3 protein were higher in cells incubated in
serum-containing medium compared with those incubated
under serum-free conditions, except in the presence of 30
μmol/L lutein. No signiﬁcant changes in total cholesterol
content or biosynthesis of [14C]cholesterol from [14C]acetate
(Table 1) occurred following lutein treatment. Efﬂux of [3H]-
cholesterol to apoA-I (10 μg/mL), although modest, was
signiﬁcantly higher than that in the absence of any choles-
terol acceptor; however, this signiﬁcance was lost in cells
exposed to 10–30 μmol/L lutein (Table 1). Efﬂux of [3H]c-
holesterol to HDL (50 μg/mL) was higher than to apoA-I:
modest inhibitions of [3H]cholesterol efﬂux were noted at 3
μmol/L lutein (15%; P < 0.05) and 10 μmol/L lutein (16%; P <
0.01) (Fig. 1B). Release of insulin was not signiﬁcantly
increased by prior incubation with HDL (50 μg/mL; 24 h)
under basal conditions, but in the presence of 10 μmol/L
lutein, the stimulatory effect of HDL (50 μg/mL) proved sig-
niﬁcant (1.43-fold; P < 0.05) (Fig. 1C).
Finally, BRIN-BD11 cells were genetically manipulated so
that STARD3 was stably overexpressed or StarD3 stably
repressed (Fig. 1D). Compared with empty vector (pCMV6)
control (EV), overexpression of STARD3 had no effect on
efﬂux of [3H]cholesterol, under basal conditions or in the
presence of HDL (50 μg/mL) (Fig. 1E); levels of efﬂux were
comparable with wild type cells. Efﬂux to apoA-I (10 μg/mL)
also remained unaffected by STARD3 overexpression,
compared with EV control (data not shown). Equally,
stable knockdown of endogenous StarD3 had no impact on
cholesterol efﬂux under basal conditions, or in the presence
of HDL, compared with the negative short hairpin plasmid
(Fig. 1E); insulin release also remained unaffected by
changes of STARD3/StarD3 expression within a 5-fold range
(Fig. 1F).
The present study demonstrates that endosomal choles-
terol trafﬁcking protein, StarD3, does not appear to be reg-
ulated by increases in total cholesterol content, or by marked
alterations in cholesterol ﬂux between differing cellular pools
in BRIN-BD11 cells. This was a surprising outcome, as
expression of STARD3 was clearly sterol-dependent in
human THP-1 macrophages (Borthwick et al., 2009) and
repressed by genetic obesity in both male and female fa/fa
rats (Sofﬁentini et al., 2014). The promoter regions of both rat
and human StarD3/STARD3 contain putative binding sites
for lipid responsive transcription factors, such as peroxisome
proliferator activated receptors, retinoid X receptors and
SREBPs (Borthwick et al., 2009), while the marked increa-
ses in cholesterol biosynthesis observed in response to
cholesterol depletion (Table 1) suggest that SREBP-depen-
dent induction of HMG CoA reductase is operating correctly.
Thus, it seems that expression of StarD3 protein seems to
be dissociated from the cholesterol homeostatic ‘machinery’
in BRIN-BD11 cells.
Further, the StarD3 ligand, lutein (Li et al., 2011), did not
alter cellular levels of StarD3, suggesting no changes in
stability/degradation of this protein, but subtle changes in
sterol metabolism were observed in cells exposed to this
carotenoid. Cholesterol efﬂux to apoAI and HDL were
diminished by treatment with lutein, and insulin release
moderated so that a signiﬁcant stimulation was seen in the
presence of HDL. Recombinant StarD3 selectively binds
lutein with high afﬁnity (Kd = 0.45 μmol/L) and in macular
retina localises to the cone inner segments and axons,
where it is thought to facilitate the uptake of lutein (Li et al.,
2011) Studies linking lutein with cholesterol efﬂux from cells
are lacking, but this molecule is transported in HDL and
binds to SR-B1 (Kijlstra et al., 2012), so that the modest
reductions in efﬂux noted here could reﬂect competition for
SR-B1 occupancy. Alternatively, increased cellular choles-
terol content, as a result of reduced efﬂux (Fig 1B) or
enhanced uptake of cholesterol via SR-B1, may explain the
increased insulin release seen in the presence of both lutein
and HDL (Fig 1C).
Finally, genetic manipulation of levels of StarD3 protein
within a 5-fold range did not impact on either HDL efﬂux or
insulin release from stably transfected BRIN-BD11 cell lines.
The former outcome is consistent with the lack of sterol
regulation of StarD3 in these cells, but contrasts markedly
with ﬁndings in other studies. Overexpression of STARD3
increased ABCA1 protein levels, and cholesterol efﬂux in
human THP-1 macrophages (Borthwick et al., 2010) and
increased lipidation of exogenous apoA-I in McRH-7777
hepatoma cells (Sofﬁentini et al., 2014). Indeed, StarD3 can
access cholesterol in ‘early’ late endosomes and facilitate
recycling of this sterol to the plasma membrane, aid the
formation of inter-organelle membrane contact sites between
late endosomes and the ER, and deliver cholesterol to
mitochondria (van der Kant et al., 2013; Alpy et al., 2013);
StarD3 is also thought to be involved in actin-mediated
dynamics of late endocytic organelles (Holtta-Vuori et al.,
2005). One possible reason for the lack of impact resulting
from changes in StarD3 expression in insulinoma cells may
be that insulin granules are major sites of intracellular
cholesterol accumulation, distinct from non-secretory cell
StarD3 in insulinoma cells LETTER
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types in which cholesterol concentrates in recycling endo-
somes and trans-Golgi network. This resonates with reports
that insulin release is sensitive to inhibition of cholesterol
biosynthesis, but not lipoprotein depletion from media (Rutti
et al., 2009; Zuniga-Hertz et al., 2015) and suggests that if
cholesterol derived from the endocytic pathway does con-
tribute to that found in insulin secretory granules, then it does
so in a StarD3 independent manner, either at an earlier stage
than that facilitated by StarD3, or via other cholesterol traf-
ﬁcking proteins. Certainly, genetic deletion of the START
domain of StarD3 in mice is not associated with development
of diabetes or major changes in lipid metabolism (Kishida
et al., 2004).
Overall, while enrichment and depletion of cholesterol
moderates insulin release from BRIN-BD11 cells, endosomal
cholesterol trafﬁcking protein StarD3 does not appear to be
regulated by substantial changes in sterol metabolism in
BRIN-BD11 cells. Lutein, a StarD3 ligand, decreases
cholesterol efﬂux to ApoA-I and HDL, but genetic overex-
pression and knockdown of StarD3 does not alter cholesterol
metabolism or insulin release. Thus, while StarD3 is
expressed in BRIN-BD11 cells, it is not sterol-regulated, and
appears functionally distinct from the rest of the cholesterol
homeostasis ‘machinery’ which sustains cholesterol at levels
required for effective insulin release
FOOTNOTES
Abbreviations: ABCA1 ( ATP binding cassette transporter A1);
ABCG1 (ATP binding cassette transporter G1); ApoA-I
(Apolipoprotein A-I); CLC (Cholesterol-lipid concentrate); Gapdh
(Glyceraldehyde-3-phosphate dehydrogenase); GSIS (Glucose-
stimulated insulin secretion); HDL (High density lipoprotein); LDL
(Low density lipoprotein); LDLR (LDL receptor); MCD (Methyl–cy-
clodextrin); SR-B1 (Scavenger receptor B1); StAR (Steroidogenic
acute regulatory protein); StarD3 (StAR-related lipid transfer domain
3); START (StAR-related lipid transfer protein).
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